RosettaGX Next-Gen is a menu of tests that leverage industry-leading Next-Generation Sequencing (NGS) technology to guide clinicians to the most appropriate treatment for patients. These panels offer a high-depth of coverage that can pick up low-frequency mutations, allowing physicians to more easily decipher actionable mutations from distracting, inactionable ones.

ROSETTAGX NEXT-GEN PANEL APPLICATIONS:

Genome-wide oncogenomic tumor profiling

Pharmacogenomic toxicity analysis

Patient stratification in clinical trials

Targeted therapy for lung cancer patients via OncoGxLung

OncoGxOne

OncoGxOne™ is an NGS-platform panel that detects 64 genomic alterations critical to cancer. The results include clear, concise, and actionable clinical recommendations from a single, comprehensive test.*

Interrogates all types of genomic aberrations in 64 cancer genes, specifically 56 related to cancer-targeted therapy and 8 related to chemotherapy

Interrogates all types of genomic aberrations in 64 cancer genes, specifically 56 related to cancer-targeted therapy and 8 related to chemotherapy

Cost-effective: provides comprehensive coverage of relevant genetic alterations in a single test

Easy to read report with “Key Findings” highlighted

Detects point mutations, copy number variations, gene fusions, and insertions/deletions

Rapid turnaround time of 7-10 days

Interrogates All Types Of Genomic Aberrations In 64 Cancer Genes

View markers by:
ABL1 BRAF CTNNB1 ESR1 HRAS MET PDGFRA RUNX1
AKT1 BRCA1 CYP2C8 ETV6 IDH1 MLL PDGFRB SMO
ALK BRCA2 CYP2D6 FGFR1 IDH2 MPL PIK3CA TP53
ATM CCND1 DDR2 FGFR2 JAK1 MTHFR PTCH1 TPMT
AURKA CCNE1 DNMT3A FGFR3 JAK2 MYC PTEN TSC1
BCL2 CDK4 DPYD FLT3 KIT NF1 RARA TYMS
BCL6 CEBPA EGFR GNA11 KRAS NPM1 RET UGT1A1
BCR CRLF2 ERBB2 GNAQ MAP2KI NRAS ROS1 XRCC1

*OncoGxOne and OncoGxLung are performed by and interpreted by Admera Health

OncoGxLung

OncoGxLung is a lung-specific panel that detects point mutations, small insertions/deletions, and gene fusions to provide clinically actionable results.*

Interrogates five genes associated with highly-prevalent lung cancer types: EGFR, ROS1, ALK, KRAS, and BRAF

Identifies mutations in exons 18, 19, 20, and 21 of EGFR and exons 2 and 3 of KRAS

Covered by most payers as testing results in cost-effective care decisions

Rapid turnaround time of 7-10 days

*OncoGxOne and OncoGxLung are performed by and interpreted by Admera Health